Trial Profile

A phase 2 study of REGN1979 in patients with Diffuse Large B-Cell Lymphoma and non-Hodgkin lymphoma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 12 Feb 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Odronextamab (Primary)
Indications Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
Focus Registrational; Therapeutic Use

Most Recent Events

05 Feb 2021 According to a Regeneron Pharmaceuticals media release, enrollment is expected to be completed in 2021.
06 Nov 2019 According to a Regeneron Pharmaceuticals media release, the patients are currently enrolled in this study.
06 Nov 2019 According to a Regeneron Pharmaceuticals media release, data from this study will be presented at the 2019 American Society of Hematology (ASH) Annual Meeting, Dec 2019.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com